Andrew M. Asberry
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
Publications
25
Citations
232
Est. group size
~2
Recurring co-author estimate
Active years
11
Publishing since 2015
Andrew M. Asberry's research focuses on prostate cancer biology, particularly how a protein called PRMT5 (an enzyme that chemically modifies other proteins to regulate gene activity) contributes to cancer progression, including treatment resistance and a form of prostate cancer called neuroendocrine differentiation. This work explores PRMT5 as a potential drug target and examines its role in androgen receptor signaling, a key pathway in prostate cancer growth.
Publication output was minimal to modest from 2017-2022, with a sharp spike in 2023 (largely supplementary materials tied to a single study), followed by little activity in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- PRMT5:MEP50 Are Mediators of Treatment‐Induced Neuroendocrine Differentiation in Prostate Cancer
The Prostate · 2025
- Data from Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer
2023
- Supplementary Figures from Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer
2023
- Supplementary Table S1 from Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer
2023
- Supplementary Methods from Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer
2023
- Supplementary Table S1 from Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer
2023
- Supplementary Methods from Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer
2023
- Supplementary Figures from Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer
2023
- Data from Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer
2023
- PRMT5: a putative oncogene and therapeutic target in prostate cancer
Cancer Gene Therapy · 2021
- 3506 PRMT5 is a novel therapeutic target to enhance radiation therapy for cancer treatment
Journal of Clinical and Translational Science · 2019
- iScience×1
- Cancer Gene Therapy×1
- Cancer Research×1
- Journal of Medicinal Chemistry×1
- Computational and Structural Biotechnology Journal×1
- Xuehong Deng
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Chang‐Deng Hu
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Rami A. Alfar
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Bennett D. Elzey
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Dipankor Chatterjee
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile